Perceptual disturbances associated with low-dose bupropion sustained-release treatment [21]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 543-544

  Liu, Chia Yih ^a   Chien, Yuan Shun ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b EN CHU KONG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; PAROXETINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DROWSINESS; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; LETTER; LOW DRUG DOSE; MAJOR DEPRESSION; PERCEPTION DISORDER; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINATIONS; HUMANS;

EID: 34548680742     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31814fb98e     Document Type: Letter

References (8)

1. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56: 395-401.
2. Ames D, Wirshing WC, Szuba MP. Organic mental disorders associated with bupropion in three patients. J Clin Psychiatry. 1992;53: 53-55.
3. Becker RE, Dufresne RL. Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry. 1982;139:1200-1201.
4. Golden RN, James SP, Sherer MA, et al. Psychoses associated with bupropion treatment. Am J Psychiatry. 1985;142:1459-1462.
5. Howard WT, Warnock JK. Bupropion-induced psychosis. Am J Psychiatry. 1999;156: 2017-2018.
6. Neumann M, Livak V, Paul HW, et al. Acute psychosis after administration of bupropion hydrochloride (Zyban). Pharmacopsychiatry. 2002;35:247-248.
7. Wang TS, Shiah IS, Yeh CB, et al. Acute psychosis following sustained release bupropion overdose. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:149-151.
8. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159-166.